Skip to main content
SpringerLink
Log in
Book cover

Delta Opioid Receptor Pharmacology and Therapeutic Applications pp 179–197Cite as

Delta Opioid Receptors and Modulation of Mood and Emotion

  • Chapter
  • First Online:

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 247))

Abstract

Depression is a pervasive and debilitating mental disorder that is inadequately treated by current pharmacotherapies in a majority of patients. Although opioids have long been known to regulate mood states, the use of opioids to treat depression is rarely discussed. This chapter explores the preclinical and clinical evidence supporting the antidepressant-like effects of opioid ligands, and in particular, delta opioid receptor (DOR) agonists. DOR agonists have been shown to produce antidepressant-like effects in a number of animal models. Some DOR agonists also produce convulsions which has limited their clinical utility. However, DOR agonists that generate antidepressant-like effects without convulsions have recently been developed and these drugs are beginning to be evaluated in humans. Work investigating potential mechanisms of action for the antidepressant-like effects of DOR agonists is also explored. Understanding mechanisms that give rise to DOR-mediated behaviors is critical for the development of DOR drugs with improved safety and clinical utility, and future work should be devoted to elucidating these pathways.

This is a preview of subscription content, log in via an institution.

Change history

  • 16 July 2019

    The book was inadvertently published with error in the following chapters.

References

  • Aceto MD, May EL, Harris LS, Bowman ER, Cook CD (2007) Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Eur J Pharmacol 566:88–93

    CAS  PubMed  PubMed Central  Google Scholar 

  • Aguila B, Coulbault L, Boulouard M, Léveillé F, Davis A, Tóth G, Borsodi A, Balboni G, Salvadori S, Jauzac P, Allouche S (2007) In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br J Pharmacol 152:1312–1324. Erratum in: Br J Pharmacol. 152: 1325

    CAS  PubMed  PubMed Central  Google Scholar 

  • American Psychiatric Association (2013) Major depressive disorder. In: Desk reference to the diagnostic criteria from DSM-5, Washington

    Google Scholar 

  • Anderson IM, Cowen PJ, Grahame-Smith DG (1990) The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 100:498–503

    CAS  PubMed  Google Scholar 

  • Baamonde A, Daugé V, Ruiz-Mayo M, Fulga IG, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 stimulation. Eur J Pharmacol 216:157–166

    CAS  PubMed  Google Scholar 

  • Baghai TC (2008) Electroconvulsive therapy and its different indications. Dialogues Clin Neurosci 10:105–117

    PubMed  PubMed Central  Google Scholar 

  • Bie B, Zhu W, Zhizhong ZP (2009) Rewarding morphine-induced synaptic function of δ-opioid receptors on central glutamate synapses. J Pharmacol Exp Ther 329:290–296

    CAS  PubMed  PubMed Central  Google Scholar 

  • Billet F, Dourmap N, Costentin J (2004) Involvement of corticostriatal glutamatergic terminals in striatal dopamine release elicited by stimulation of δ-opioid receptors. Eur J Neurosci 20:2629–2638

    PubMed  Google Scholar 

  • Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillsosi L, Ventriglia M, Riva MA, Gennarelli M (2010) Serum and plasma BDNF levels in major depression: a replication study and meta-anaylses. World J Biol Psychiatry 11:763–773

    PubMed  Google Scholar 

  • Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15:49–57

    CAS  PubMed  Google Scholar 

  • Bosse KE, Jutkiewicz EM, Schultz-Kuszak KN, Mabrouk OS, Kennedy RT, Gnegy ME, Traynor JR (2014) Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism. Neuropharmacology 77:19–27

    CAS  PubMed  Google Scholar 

  • Bradbury FA, Zelnik JC, Traynor JR (2009) G protein independent phosphorylation and internalization of the delta-opioid receptor. J Neurochem 109:1526–1535

    CAS  PubMed  PubMed Central  Google Scholar 

  • Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002a) Nonpeptidic delta-opioid agonists reduce immobility in forced swim assay in rats. Neuropsychopharmacology 26:744–755

    CAS  PubMed  Google Scholar 

  • Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002b) Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology 164:42–48

    CAS  PubMed  Google Scholar 

  • Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161

    PubMed  PubMed Central  Google Scholar 

  • Charfi I, Nagi K, Mnie-Filali O, Thibault D, Balboni G, Schiller PW, Trudeau LE, Pineyro G (2014) Ligand- and cell-dependent determinants of internalization and cAMP modulation by DOR (DOR) agonists. Cell Mol Life Sci 71:1529–1546

    CAS  PubMed  PubMed Central  Google Scholar 

  • Charfi L, Audet N, Bagheri Tudashki H, Pineyro G (2015) Identifying ligand-specific signaling within biased responses: focus on d opioid receptor ligands. Br J Pharmacol 172:435–448

    CAS  PubMed  Google Scholar 

  • Chiang T, Sansuk K, van Rijn RM (2016) β-Arrestin 2 dependence of δ opioid receptor agonists is correlated with alcohol intake. Br J Pharmacol 173:332–343

    CAS  PubMed  Google Scholar 

  • Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR, Mosberg HI, Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267:888–895

    CAS  PubMed  Google Scholar 

  • Darko DF, Risch SC, Gillan JC, Golshan S (1992) Association of beta-endorphin with specific clinical symptoms of depression. Am J Psychiatry 149:1162–1167

    CAS  PubMed  Google Scholar 

  • Deo AJ, Huang YY, Hodgkinson CA, Xin Y, Oguendo MA, Dwork AJ, Arango V, Brent DA, Goldman D, Mann JJ, Haghighi F (2013) A large-scale candidate gene analysis of mood disorders: evidence of neurotrophic tyrosine kinase receptor and opioid receptor signaling dysregulation. Psychiatr Genet 23:47–55

    CAS  PubMed  Google Scholar 

  • Djurović D, Milić-Askrabić J, Majkić-Singh N (1999) Serum beta-endorphin level in patients with depression on fluvoxamine. Farmaco 54:130–133

    PubMed  Google Scholar 

  • Do Carmo GP, Folk JE, Rice KC, Chartoff E, Carlezon WA Jr, Negus SS (2009) The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol 604:58–65

    PubMed  Google Scholar 

  • Dripps IJ, Wang Q, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM (2017) The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. Psychopharmacology 234(1):29–39. https://doi.org/10.1007/s00213-016-4432-5. [Epub ahead of print]

    Article  CAS  PubMed  Google Scholar 

  • Duman RS (2003) Role of neurotrophic factors in the etiology and treatment of mood disorders. NeuroMolecular Med 5:11–25

    Google Scholar 

  • Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60:804–815

    CAS  PubMed  Google Scholar 

  • Eisendrath SJ, Lichtmacher JE (2014) Psychiatric disorders. In: Papadakis MA, SJ MP, Rabow MW (eds) Current medical diagnosis & treatment 2014. McGraw-Hill, New York. Chapter 25

    Google Scholar 

  • Emrich HM, Höllt V, Kissling W, Fischler M, Laspe H, Heinemann H, von Zerssen D, Herz A (1979) Beta-endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmakopsychiatr Neuropsychopharmakol 12:269–276

    CAS  PubMed  Google Scholar 

  • Emrich HM, Vogt P, Herz A (1981) A possible role of opioids in depression: significant improvement after buprenorphine. Biol Psychiatry 16:380–385

    Google Scholar 

  • Everett GM (1966) The Dopa response potentiation test and its use in screening for anti-depressant drugs. In: Garattini S, Dukes MNG (eds) Anti-depressant drugs. Excerpta Medica Foundation, Amsterdam

    Google Scholar 

  • Extein I, Pickar D, Gold MS, Gold PW, Pottash AL, Sweeney DR, Ross RJ, Rebard R, Martin D, Goodwin FK (1981) Methadone and morphine in depression. Psychopharmacol Bull 17:29–33

    CAS  PubMed  Google Scholar 

  • Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, Lucki I (2016) Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology 41:2344–2351

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Wardern D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172

    PubMed  Google Scholar 

  • Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200

    CAS  PubMed  Google Scholar 

  • Fink M, Shapiro DM (1969) EEG patterns as an index of clinical activity of psychoactive drugs. Electroencephalogr Clin Neurophysiol 27(7):710

    CAS  PubMed  Google Scholar 

  • Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, Reinalda MS, McGrath PJ, van Zastrow M, Slager SL, Hamilton SP (2010) Association of mu-opioid receptor variants and response to citalopram in major depressive disorder. Am J Psychiatry 167:565–573

    PubMed  PubMed Central  Google Scholar 

  • Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D (2014) The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Transl Psychiatry 4:e411. https://doi.org/10.1038/tp.2014.30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Genazzani AR, Petraglia F, Facchinetti F, Monittola C, Scarone S, Brambilia F (1984) Opioid plasma levels in primary affective disorders. Effect of desimipramine therapy. Neuropsychobiology 12:78–85

    CAS  PubMed  Google Scholar 

  • Gerner RH, Catlin DH, Gorelick DA, Hui KK, Li CH (1980) Beta-endorphin infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry 37:642–647

    CAS  PubMed  Google Scholar 

  • Goodwin GM, Austin MP, Curran SM, Ross M, Murray C, Prentice N, Ebmeier KP, Bennie J, Carrol S, Dick H, Fink G (1993) The elevation of plasma β-endorphin levels in major depression. J Affect Disord 29:281–289

    CAS  PubMed  Google Scholar 

  • Gotoh L, Saitoh A, Yamada M, Fujii H, Nagase H, Yamada M (2016) Effects of repeated treatment with a DOR agonist KNT-127 on hyperemotionality in olfactory-bulbectomized rats. Behav Brain Res 32:11–14. https://doi.org/10.1016/j.bbr.2016.11.008

    Article  CAS  Google Scholar 

  • Hameroff SR, Cork RC, Scherer K, Crago BR, Neuman C, Womble JR, Davis TP (1982) Doxepin effects on chronic pain, depression and plasma opioids. J Clin Psychiatry 43:22–27

    CAS  PubMed  Google Scholar 

  • Hayes AG, Skingle M, Tyers MB (1986) Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat. Br J Pharmacol 88:867–872

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang P, Tunis J, Parry C, Tallarida R, Liu-Chen LY (2016) Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test. Eur J Pharmacol 781:53–59

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W (2011) Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor. J Pharmacol Exp Ther 338:195–204

    CAS  PubMed  Google Scholar 

  • Hudzik TJ, Pietras MR, Caccese R, Bui KH, Yocca F, Paronis CA, Swedberg MD (2014) Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse. Pharmacol Biochem Behav 124:48–57

    CAS  PubMed  Google Scholar 

  • Inturrisi CE, Alexopoulos G, Lipman R, Foley K, Roosier J (1982) Beta-endorphin immunoreactivity in the plasma of psychiatric patients receiving electroconvulsive treatment. Ann N Y Acad Sci 398:413–423

    CAS  PubMed  Google Scholar 

  • Javelot H, Messaoudi M, Garnier S, Rougeot C (2010) Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J Physiol Pharmacol 61:355–362

    CAS  PubMed  Google Scholar 

  • Jungkunz G, Nedopil N, Rüther E (1983) Acute effects of the synthetic analogue of methionine enkephalin analogue FK 33-824 on depressive symptoms. Pharmacopsychiatria 16:90–92

    CAS  PubMed  Google Scholar 

  • Jutkiewicz EM, Roques BO (2012) Endogenous opioids as physiological antidepressants: complementary role of δ receptors and dopamine. Neuropsychopharmacology 37:303–304

    CAS  PubMed  Google Scholar 

  • Jutkiewicz EM, Kaminsky ST, Rice KC, Traynor JR, Woohs JH (2005a) Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther 315:414–422

    Google Scholar 

  • Jutkiewicz EM, Rice KC, Traynor JR, Woods JH (2005b) Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology 182:588–596

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH (2006a) The convulsive and electroencephalographic changes produced by nonpeptidic d-opioid agonists in rats: comparison with pentylenetetrazol. J Pharmacol Exp Ther 317:1337–1348

    CAS  PubMed  Google Scholar 

  • Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, Watson SJ, Woods JH (2006b) Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant-like effects. Eur J Pharmacol 531:151–159

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kabli N, Nguyen T, Balboni G, O'Dowd BF, George SR (2014) Antidepressant-like and anxiolytic-like effects following activation of the μ-δ opioid receptor heteromer in the nucleus accumbens. Mol Psychiatry 19:986–994

    CAS  PubMed  Google Scholar 

  • Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y (1995) Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci 56:PL285–PL290

    CAS  PubMed  Google Scholar 

  • Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005) Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136:29–37

    CAS  PubMed  Google Scholar 

  • Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF III (2014) Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry 75:785–793

    Google Scholar 

  • Kastin AJ, Scollan EL, Ehrensing RH, Schally AV, Coy DH (1978) Enkephalin and other peptides reduce passiveness. Pharmacol Biochem Behav 9:515–519

    CAS  PubMed  Google Scholar 

  • Kennedy SE, Koepper RA, Young EA, Zubiet JK (2006) Dysregulation of endogenous opioid emotion regulatory circuitry in major depression in women. Arch Gen Psychiatry 63:1199–1208

    CAS  PubMed  Google Scholar 

  • Kita A, Imano K, Seto Y, Yakuo I, Deguchi T, Nakamura H (1997) Antinociceptive and antidepressant-like profiles of BL-2401, a novel enkephalinase inhibitor, in mice and rats. Jpn J Pharmacol 75:337–346

    CAS  PubMed  Google Scholar 

  • Kline NS, Li CH, Lehmann HE, Lajtha A, Laski E, Cooper T (1977) Beta-endorphin-induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 34:1111–1113

    CAS  PubMed  Google Scholar 

  • Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE (2008) Potent, orally bioavailable DOR agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem 51:5893–5896

    PubMed  Google Scholar 

  • Le Merrer J, Becker JAJ, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379–1412

    PubMed  Google Scholar 

  • Lee BH, Kim YK (2010) The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 7:231–235

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lindström LH, Widerlöv E, Gunne LM, Wahlström A, Terenius L (1978) Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states. Acta Psychiatr Scand 57:153–164

    PubMed  Google Scholar 

  • Longoni R, Cadoni C, Mulas A, Di Chiara G, Spina L (1998) Dopamine-dependent behavioural stimulation by non-peptidic delta opioids BW373U86 and SNC80: 2. Place-preference and brain microdialysis studies in rats. Behav Pharmacol 9:9–14

    CAS  PubMed  Google Scholar 

  • Loosen PT, Shelton RC (2008) Mood disorders. In: Ebert MH, Loosen PT, Nurcombe B, Leckman JF (eds) CURRENT diagnosis & treatment: psychiatry, 2e. McGraw-Hill, New York. Chapter 18

    Google Scholar 

  • Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36:195–206

    CAS  PubMed  Google Scholar 

  • Mabrouk OS, Marti M, Salvadori S, Morari M (2009) The novel DOR agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience 164:360–369

    CAS  PubMed  Google Scholar 

  • Monteggia LM, Zarate C Jr (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139–143

    CAS  PubMed  PubMed Central  Google Scholar 

  • Naber D, Pickar D, Post RM, Van Kammen DP, Waters RN, Ballenger JC, Goodwin FK, Bunney WE Jr (1981) Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry 138:1457–1462

    CAS  PubMed  Google Scholar 

  • Nagase H, Tanaka T, Saitoh A (2002) Therapeutics of preventive medicines for mood disorders or anxiert disorders. U.S. Patent WO/2002/002117

    Google Scholar 

  • Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD (2007) NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action. Eur J Pharmacol 566:132–136

    CAS  PubMed  PubMed Central  Google Scholar 

  • Negus SS, Gatch MB, Mello NK, Zhang X, Rice K (1998) Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in monkeys. J Pharmacol Exp Ther 286:362–375

    CAS  PubMed  Google Scholar 

  • Negus SS, Rosenberg MB, Altarifi AA, O'Connell RH, Folk JE, Rice KC (2012) Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats. J Pain 13:317–327

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nozaki C, Nagase H, Nemoto T, Matifas A, Kieffer BL, Gaveriaux-Ruff C (2014) In vivo properties of KNT-127, a novel δ opioid receptor agonist: receptor internalization, antihyperalgesia, and antidepressant effects in mice. Br J Pharmacol 171:5376–5386

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nyhuis PW, Gastpar M, Scherbaum N (2008) Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 28:593–595

    PubMed  Google Scholar 

  • Plotnikoff NP, Kastin AJ, Coy DH, Christensen CW, Schally AV, Sprites MA (1976) Neuropharmacological actions of enkephalin after systemic administration. Life Sci 19:1283–1288

    CAS  PubMed  Google Scholar 

  • Pradhan AA, Perro J, Walwyn WM, Smith ML, Vicente-Sanchez A, Segura L, Bana A, Keiffer BL, Evans CJ (2016) Agonist-specific recruitment of arrestin isforms differentially modify DOR function. J Neurosci 36:3541–3551

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rahman A, Patel V, Maselko J, Kirkwood B (2008) The neglected ‘m’ in MCH programmes–why mental health of mothers is important for child nutrition. Trop Med Int Health 13:579–583

    PubMed  Google Scholar 

  • Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, Duncan WC, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Cross A, Smith MA, Zarate CA Jr (2016) A randomized, placebo-controlled pilot trial of the DOR agonist AZD2327 in anxious depression. Psychopharmacology 233:1119–1130

    CAS  PubMed  PubMed Central  Google Scholar 

  • Robbins TW, Arnsten AF (2009) The neuropsychopharmacology of executive function: monoaminergic modulation. Annu Rev Neurosci 32:267–287

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sackeim HA (1999) The anticonvulsant hypothesis of the mechanisms of ECT: current status. J ECT 15:5–26

    CAS  PubMed  Google Scholar 

  • Saitoh A, Yamada M, Yamada M, Takahashi K, Yamaguchi K, Murasawa H, Nakatani A, Tatsumi Y, Hirose N, Kamei J (2008) Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res 1208:160–169

    CAS  PubMed  Google Scholar 

  • Saitoh A, Sugiyama A, Nemoto T, Fujii H, Wada K, Oka J, Nagase H, Yamada M (2011) The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behav Brain Res 223:271–279

    CAS  PubMed  Google Scholar 

  • Saitoh A, Sugiyama A, Yamada M, Inagaki M, Oka J, Nagase H, Yamada M (2013) The novel δ opioid receptor agonist KNT-127 produces distinct anxiolytic-like effects in rats without producing the adverse effects associated with benzodiazepines. Neuropharmacology 67:485–493

    CAS  PubMed  Google Scholar 

  • Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63–77

    CAS  PubMed  Google Scholar 

  • Spahn V, Stein C (2016) Targeting DORs for pain treatment: drugs in phase I and II clinical development. Expert Opin Investig Drugs. https://doi.org/10.1080/13543784.2017.1275562. [Epub ahead of print]

    CAS  PubMed  Google Scholar 

  • Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, Russo SJ, Vialou V, Caldarone BJ, Tamminga CA, Nestler EJ, Zachariou V (2013) Regulator of G protein signaling 4 is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci U S A 110:8254–8259

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sugiyama A, Nagase H, Oka J, Yamada M, Saitoh A (2014) DOR(2)-selective but not DOR(1)-selective antagonist abolishes anxiolytic-like effects of the δ opioid receptor agonist KNT-127. Neuropharmacology 79:314–320

    CAS  PubMed  Google Scholar 

  • Tanahashi S, Ueda Y, Nakajima A, Yamamura S, Nagase H, Okada M (2012) Novel δ1-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex. Neuropharmacology 62:2057–2067

    CAS  PubMed  Google Scholar 

  • Tanaka E, North RA (1994) Opioid actions on rat anterior cingulate cortex neurons in vitro. J Nerurosci 14:1106–1113

    CAS  Google Scholar 

  • Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gilbert-Rahola J (1993) Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol Psychiatry 34:100–107

    CAS  PubMed  Google Scholar 

  • Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gilbert-Rahola J (1995) Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52:145–152

    CAS  PubMed  Google Scholar 

  • Tejedor-Real P, Micó JA, Smadja C, Maldonado R, Roques BP, Gilbert-Rahola J (1998) Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 354:1–7

    CAS  PubMed  Google Scholar 

  • Torregrossa MM, Isgor C, Folk JE, Rice KC, Watson SJ, Woods JH (2004) The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 29:649–659

    CAS  PubMed  Google Scholar 

  • Torregrossa MM, Folk JE, Rice KC, Watson SJ, Woods JH (2005) Chronic administration of the DOR agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats. Psychopharmacology 183:31–40

    CAS  PubMed  PubMed Central  Google Scholar 

  • Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH (2006) Peptidic DOR agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 1069:172–181

    CAS  PubMed  Google Scholar 

  • Tortella FC, Long JB, Hong JS, Holaday JW (1989) Modulation of endogenous opioid systems by electroconvulsive shock. Convuls Ther 5:261–273

    Google Scholar 

  • Traynor JR, Fantegrossi W, Woods JH (2005) Evaluation of compounds for opioid activity. In: Dewey WL (ed) Problems of drug dependence, 2004: proceedings of the 66th annual scientific meeting; the Committee on Problems of Drug Dependence, Inc., NIDA Research Monograph. U.S. Department of Health and Human Services, Rockville, pp 131–159

    Google Scholar 

  • Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz B, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, STAR*D Study Team (2006a) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252

    CAS  PubMed  Google Scholar 

  • Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team (2006b) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40

    PubMed  Google Scholar 

  • Vergura R, Balboni G, Spagnolo B, Gavioli E, Lambert DG, McDonald J, Trapella C, Lazarus LH, Regoli D, Guerrini R, Salvadori S, Caló G (2008) Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective DOR agonist. Peptides 29:93–103

    CAS  PubMed  Google Scholar 

  • Violin JD (2014) Biased ligands at mu and DORs: targeting selective signalling to develop improved therapeutics. In: International narcotic research conference 2014, p 22

    Google Scholar 

  • World Health Organization (2008) The global burden of disease 2004 update. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf

    Google Scholar 

  • World Health Organization (2012) Depression: a global public health concern. http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf

    Google Scholar 

  • Yang QZ, Lu SS, Tian XZ, Yang AM, Ge WW, Chen Q (2011) The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice. Neurosci Lett 489:131–135

    CAS  PubMed  Google Scholar 

  • Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, Koeppe RA (2003) Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60:1145–1153

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA

    Isaac J. Dripps & Emily M. Jutkiewicz

Authors
  1. Isaac J. Dripps
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily M. Jutkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily M. Jutkiewicz .

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA

    Emily M. Jutkiewicz

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Dripps, I.J., Jutkiewicz, E.M. (2017). Delta Opioid Receptors and Modulation of Mood and Emotion. In: Jutkiewicz, E. (eds) Delta Opioid Receptor Pharmacology and Therapeutic Applications. Handbook of Experimental Pharmacology, vol 247. Springer, Cham. https://doi.org/10.1007/164_2017_42

Download citation

Publish with us

Policies and ethics

Search

Navigation